Affimed opens US operations and makes key US-based hires

23 June 2015

German clinical stage biopharma company Affimed NV (Nasdaq: AFMD) has established operations in the USA.

Affimed, focused on discovering and developing highly targeted cancer immunotherapies, also announced that Caroline Stewart and Oscar Kashala have joined the company as head of investor relations and communication and vice president, Medical US, respectively.

Ms Stewart joins Affimed from HC Wainwright, where she served as managing director and senior biotechnology analyst. During her tenure as senior biotechnology analyst and VP at Piper Jaffray she was named Wall Street Journal's "Best on the Street" (#4) and Financial Times/Starmine #3 Best Stock Picker 2008. More recently, she served as director of investor relations at Merck KGaA and also as a senior manager of US finance for Sanofi's oncology drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK